From the introduction of anti-retroviral therapy (ART) in the mid-1990’s, to the discovery of medicines that prevent the transmission of HIV, America’s biopharmaceutical companies are leading the fight against HIV/AIDS. In recent years, combination therapies have further transformed the lives of patients with HIV/AIDS so that today they can take a single pill containing multiple medicines. This once-a-day model increases adherence and is a sea change from the old model of multiple medicines taken multiple times in a day.
While these scientific advancements have had a tremendous impact on the 1.1 million HIV patients in the U.S., there is still work to be done. Biopharmaceutical researchers are working to further transform the impact of this devastating disease; developing HIV/AIDS treatments that would increase the time between treatments, significantly improving patients’ quality of life, and prevent disease transmission.
Today, PhRMA, in partnership with the The AIDS Institute, announced in a new report there are 52 medicines and vaccines are currently in development to help treat and prevent HIV infection. Among the 52 medicines there are 32 antiretrovirals and antivirals, 16 vaccines and 4 cell therapies in the pipeline, including a potential first-in-class medicine intended to prevent HIV from attaching to new cells and breaking through the cell membrane.
In honor of HIV Testing Day, we are also proud to share the story of one patient through his journey of an HIV positive diagnosis; and his dedication to educating and inspiring others to get tested. Learn more about Eric’s story here.
The report was released as part of PhRMA’s GOBOLDY campaign which also released a new ad, in its Together series the showcasing the resilience of researchers like Brian and patients like James in the fight against HIV/AIDS.
Andrew Powaleny
Andrew Powaleny is the Deputy Vice President of Public Affairs at PhRMA, where he leads communications on scientific, regulatory and intellectual property issues, highlighting the biopharmaceutical industry’s efforts in developing innovative medicines and vaccines while promoting an environment that encourages necessary risk-taking. For five years starting in 2019, he launched and led PhRMA’s grassroots initiative, Voters for Cures, bringing patients and caregivers together to advocate for access to medicine and biopharmaceutical innovation. He also co-founded and co-chaired PRIDE Umbrella, a resource group for LGBTQ+ individuals. Prior to joining PhRMA in 2015, Andrew worked as a communications consultant in Washington, D.C., and as Deputy Press Secretary for the U.S. House Committee on Energy and Commerce under Chairman Fred Upton. He holds a degree in public policy and government from Eastern Connecticut State University, with a minor in music. Outside of work, Andrew enjoys exercise, musical theater and mentoring college students through The Fund for American Studies alumni association.
Andrew Powaleny
The Patient Perspective: Vaccines
New Report: Tackling chronic conditions with preventive treatment
Three things to know about the United Nations’ new HIV/AIDS report
New Report: Vaccines continue to drive improved health outcomes
Mental Health Awareness Month: Supporting loved ones and improving mental health in America
Watch: Putting patients front and center for World AIDS Day
New Report: 1,600 cancer treatments and vaccines in clinical development
Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation
Support for continued progress is critical for pediatric drug development
New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans
State policymakers can protect American innovation and help Americans live longer, healthier lives
Recognizing National Glaucoma Awareness Month
New Report More than 160 medicines in development for mental illness
ICYMI: Cancer death rate continues to decline due to treatment advances
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
New Report: Nearly 800 medicines in development to treat chronic conditions
Recognizing National Sickle Cell Awareness Month
Making coupons count for patients with HIV
Potential gene therapies bring hope to patients with sickle cell disease
Gene therapies can reduce treatment burden and costs for patients with blood disorders
Report: More than 500 medicines in development to treat disorders of the blood
Report: More than 600 medicines in development for diseases affecting women
New Report: Nearly 800 new medicines in development to treat rare diseases
World AIDS Day: Remembering those we’ve lost and exploring the continued fight against HIV/AIDS
Guest post: Continued research and development is critical for ALS patients and families
New report shows more than 260 medicines in development to fight neurodegenerative diseases
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections
Action needed to preserve the six protected classes
Report: More than 1,300 medicines and vaccines in development to help fight cancer
Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas
New report shows nearly 260 vaccines in development, including dozens for COVID-19
Nearly 400 cell and gene therapies in development to target a broad range of diseases
Nearly 140 medicines in development to treat mental illness
New report shows more than 160 medicines in development for diabetes and related conditions
New report shows nearly 20 innovative medicines in development for sickle cell disease
Changes to the six protected class policy are the wrong prescription for Medicare and HIV patients
130 medicines in development for asthma, allergies and other respiratory diseases
130 medicines in development for asthma, allergies and other respiratory diseases
New report shows nearly 300 cell and gene therapies in development
World AIDS Day 2018: Hope for the future
New report shows more than 300 skin disease medicines in development
New report details the setbacks and challenges to Alzheimer’s research
Guest post: Excellent care for LGBTQ patients requires cultural humility and specific medical knowledge
Diversity of thought fuels next generation of breakthroughs
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
A new era in Alzheimer’s innovation
New report shows over 500 medicines in development for neurological disorders
Guest post: Advancing healthy hearts for patients
New report shows 200 medicines in development for heart disease and stroke
World AIDS Day 2017: Scientific breakthroughs paving the way for an AIDS-free generation
2017 Research & Hope Awards honor innovators in mental health
Medicare Monday: Strengthening access to vaccines for seniors
Finding cures for incurable diseases
New report portrays flourishing pipeline
Medicare Monday: New report highlights progress in fighting cancer with new physician-administered medicines
More than 240 immuno-oncology treatments in development to fight cancer
ICYMI: New study shows medicines advance life expectancy for HIV patients
Biopharmaceutical industry’s success reducing disparities for African Americans
Significant progress fighting cancer: Death rate has dropped 25 percent
3 things to know about 2016 drug approvals
"More than 50 medicines and vaccines in development for HIV infection, treatment and prevention"
HIVAIDS
Medicines in Development
More than 50 medicines and vaccines in development for HIV infection, treatment and prevention
"More than 50 medicines and vaccines in development for HIV infection, treatment and prevention"